Ian Chau

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7317812/publications.pdf

Version: 2024-02-01

498 papers	34,231 citations	14644 66 h-index	4223 174 g-index
516 all docs	516 docs citations	516 times ranked	33286 citing authors

#	Article	IF	Citations
1	Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial. Gastric Cancer, 2022, 25, 197-206.	2.7	72
2	MRI-Diagnosed Tumor Deposits and EMVI Status Have Superior Prognostic Accuracy to Current Clinical TNM Staging in Rectal Cancer. Annals of Surgery, 2022, 276, 334-344.	2.1	86
3	Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2022, 22, 39-51.	1.1	0
4	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. Leukemia and Lymphoma, 2022, 63, 562-572.	0.6	4
5	Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma. EJHaem, 2022, 3, 247-248.	0.4	1
6	Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. BJS Open, 2022, 6, .	0.7	3
7	Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 59-78.	1.9	8
8	Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opinion on Drug Safety, 2022, 21, 589-597.	1.0	6
9	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology, 2022, 40, TPS224-TPS224.	0.8	3
10	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. New England Journal of Medicine, 2022, 386, 449-462.	13.9	419
11	Approach to Immunotherapy in Oesophageal Cancer. , 2022, , 31-41.		0
12	Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. Current Oncology, 2022, 29, 2174-2184.	0.9	0
13	HER2 targeted therapy in colorectal cancer: New horizons. Cancer Treatment Reviews, 2022, 105, 102363.	3.4	12
14	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia and Lymphoma, 2022, 63, 821-833.	0.6	8
15	Abstract PR012: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, PR012-PR012.	0.4	0
16	Abstract A002: Genetic and immune landscape evolution defines subtypes of MMR deficient colorectal cancer. Cancer Research, 2022, 82, A002-A002.	0.4	0
17	Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.. Journal of Clinical Oncology, 2022, 40, 4035-4035.	0.8	3
18	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. Gut, 2021, 70, 1632-1641.	6.1	24

#	Article	IF	Citations
19	Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut, 2021, 70, 1904-1913.	6.1	24
20	The FOCCUS study: a prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Supportive Care in Cancer, 2021, 29, 1443-1453.	1.0	12
21	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology, 2021, 16, 289-298.	0.5	35
22	A very rare complication of subdural haematoma: fibrinâ€associated diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2021, 192, 947-947.	1.2	2
23	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. Advances in Therapy, 2021, 38, 707-720.	1.3	5
24	Clinical Performance of Abbreviated Liver MRI for the Follow-Up of Patients With Colorectal Liver Metastases. American Journal of Roentgenology, 2021, 216, 669-676.	1.0	8
25	18 Fâ€choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. British Journal of Haematology, 2021, 193, 1026-1026.	1.2	4
26	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab Â± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clinical Cancer Research, 2021, 27, 3926-3935.	3.2	55
27	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1429-1441.	0.9	2
28	Trastuzumab deruxtecan: heralding biomarker-directed therapy in metastatic colorectal cancer. Lancet Oncology, The, 2021, 22, 739-741.	5.1	1
29	Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).. Journal of Clinical Oncology, 2021, 39, TPS3620-TPS3620.	0.8	10
30	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. Nature Ecology and Evolution, 2021, 5, 1024-1032.	3.4	16
31	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.. Journal of Clinical Oncology, 2021, 39, LBA4001-LBA4001.	0.8	65
32	Claudin 18.2â€"a FAST-moving target in gastric cancer?. Annals of Oncology, 2021, 32, 584-586.	0.6	17
33	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nature Medicine, 2021, 27, 1362-1366.	15.2	70
34	Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.. Journal of Clinical Oncology, 2021, 39, 4015-4015.	0.8	6
35	Digital histological markers based on routine H&E slides to predict benefit from maintenance immunotherapy in esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2021, 39, e16074-e16074.	0.8	1
36	Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instabilityâ€"High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncology, 2021, 7, 895.	3.4	184

#	Article	IF	Citations
37	Are treatment response assessment maps (TRAMs) and 18 Fâ€choline positron emission tomography the future of central nervous system lymphoma imaging?. British Journal of Haematology, 2021, 195, e116-e119.	1.2	2
38	Chronic lymphocytic leukaemia and Richter's transformation: multimodal review and new imaging paradigms. Clinical Radiology, 2021, 76, 789-800.	0.5	3
39	Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma. Pharmacogenomics, 2021, 22, 703-726.	0.6	3
40	Targeting the Stroma in the Management of Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 691185.	1.3	14
41	Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Review of Gastroenterology and Hepatology, 2021, 15, 1159-1167.	1.4	6
42	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 2021, 5, 4073-4082.	2.5	9
43	Whole-body diffusion-weighted MRI in lymphomaâ€"comparison of global apparent diffusion coefficient histogram parameters for differentiation of diseased nodes of lymphoma patients from normal lymph nodes of healthy individuals. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3549-3561.	1.1	3
44	1416P Genomic landscape of late-stage gastric cancer. Annals of Oncology, 2021, 32, S1062-S1063.	0.6	3
45	453P Routine DPYD mutation testing for patients receiving fluoropyrimidines for gastrointestinal (GI) cancers: Real world experience in a tertiary UK oncology centre. Annals of Oncology, 2021, 32, S559.	0.6	0
46	447P The prognostic factors in early stage BRAF mutant colorectal cancer: Experience from a large volume UK tertiary centre. Annals of Oncology, 2021, 32, S557.	0.6	0
47	LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen. Annals of Oncology, 2021, 32, S1332.	0.6	24
48	1704P Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	0
49	443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers â€" phase IIA dose finding. Annals of Oncology, 2021, 32, S555-S556.	0.6	5
50	Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology and Hepatology, 2021, 6, 933-946.	3.7	73
51	1386P Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer. Annals of Oncology, 2021, 32, S1050-S1051.	0.6	2
52	386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC). Annals of Oncology, 2021, 32, S532.	0.6	11
53	Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC).. Journal of Clinical Oncology, 2021, 39, 102-102.	0.8	20
54	Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial.. Journal of Clinical Oncology, 2021, 39, 201-201.	0.8	8

#	Article	IF	Citations
55	The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing. Journal of Clinical Medicine, 2021, 10, 215.	1.0	5
56	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. Bone Marrow Transplantation, 2021, , .	1.3	0
57	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1321-1337.	5.7	66
58	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
59	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	0.8	121
60	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
61	Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 1089-1107.	1.9	1
62	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	5.8	10
63	DCE-MRI is more sensitive than IVIM-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. Cancer Imaging, 2021, 21, 67.	1.2	4
64	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 2020, 146, 94-102.	2.3	34
65	Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. Clinical Colorectal Cancer, 2020, 19, 32-38.e3.	1.0	16
66	Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 133-141.	2.7	15
67	MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer. Clinical Cancer Research, 2020, 26, 183-192.	3.2	79
68	R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of Hematology, 2020, 99, 105-112.	0.8	6
69	Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer. Journal of Comparative Effectiveness Research, 2020, 9, 103-114.	0.6	5
70	Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data. Frontiers in Oncology, 2020, 10, 1634.	1.3	2
71	Early interval and serial positron emission tomographyâ€computed tomography (PETâ€CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. British Journal of Haematology, 2020, 190, e357-e362.	1.2	0
72	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02,) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	3.3	28

#	Article	IF	Citations
73	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. European Radiology, 2020, 30, 6702-6708.	2.3	14
74	Ramucirumab in Combination with Pembrolizumab in Treatment-NaÃ¯ve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. Cancers, 2020, 12, 2985.	1.7	21
75	439P Phase Ib/II study of ibrutinib (ibr) in combination with cetuximab (cetux) in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Annals of Oncology, 2020, 31, S428.	0.6	1
76	Molecular target: pan-AKT in gastric cancer. ESMO Open, 2020, 5, e000728.	2.0	25
77	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open, 2020, 5, e000797.	2.0	18
78	Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer. ESMO Open, 2020, 5, e000791.	2.0	25
79	1446P Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer. Annals of Oncology, 2020, 31, S909-S910.	0.6	0
80	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 2020, 10, e034527.	0.8	11
81	Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer. BMC Gastroenterology, 2020, 20, 133.	0.8	5
82	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial. Trials, 2020, 21, 431.	0.7	2
83	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. European Journal of Cancer, 2020, 135, 103-112.	1.3	11
84	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
85	Focal splenic lesions in indolent Bâ€NHL: association with high grade transformation and safe percutaneous biopsy. British Journal of Haematology, 2020, 189, e157-e160.	1.2	2
86	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	1.1	0
87	Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study. Cancers, 2020, 12, 657.	1.7	14
88	O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Annals of Oncology, 2020, 31, 236.	0.6	6
89	Emerging precision therapies for gastric cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 299-311.	0.4	1
90	Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers. Cancer Discovery, 2020, 10, 657-663.	7.7	93

#	Article	IF	Citations
91	LyRIC indeterminate response and Immuneâ€mediated pseudoprogression of diffuse large Bâ€cell lymphoma following polatuzumabâ€based salvage therapy. British Journal of Haematology, 2020, 189, e248-e251.	1.2	3
92	Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clinical Cancer Research, 2020, 26, 3546-3556.	3.2	13
93	Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open, 2020, 5, e000638.	2.0	47
94	Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treatment Reviews, 2020, 86, 101998.	3.4	25
95	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. Journal of Clinical Oncology, 2020, 38, 3089-3089.	0.8	3
96	Pembrolizumab versus paclitaxel for previously treated patients with PD-L1â€"positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.. Journal of Clinical Oncology, 2020, 38, 4503-4503.	0.8	31
97	TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancerâ€"A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).. Journal of Clinical Oncology, 2020, 38, TPS4120-TPS4120.	0.8	8
98	Pembrolizumab (pembro) in microsatellite instability-high (MSI-H) advanced gastric/gastroesophageal junction (G/GEJ) cancer by line of therapy.. Journal of Clinical Oncology, 2020, 38, 430-430.	0.8	20
99	Real-world outcomes of first-line U.S. patients with unresectable advanced or metastatic gastroesophageal adenocarcinoma by primary tumor location.. Journal of Clinical Oncology, 2020, 38, 304-304.	0.8	0
100	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. Journal of Clinical Oncology, 2020, 38, e16537-e16537.	0.8	1
101	Abstract 258: MicroRNAs as biomarkers of resistance to HER2 inhibition in combination with chemotherapy in gastro-esophageal cancer. , 2020, , .		4
102	Evaluating maintenance therapies in advanced oesophago-gastric adenocarcinoma (OGA): Interim analysis and biomarker results from the PLATFORM study.. Journal of Clinical Oncology, 2020, 38, 282-282.	0.8	1
103	Post hoc safety and effectiveness analysis of aflibercept + FOLFIRI for patients with metastatic colorectal cancer (mCRC) previously treated with antiepidermal growth factor receptor (EGFR) therapy in OZONE.. Journal of Clinical Oncology, 2020, 38, 212-212.	0.8	0
104	Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).. Journal of Clinical Oncology, 2020, 38, 712-712.	0.8	5
105	SOlar: A translational phase II study of single-agent olaparib in the treatment of advanced esophagogastric cancer.. Journal of Clinical Oncology, 2020, 38, TPS471-TPS471.	0.8	0
106	A global phase II trial-in-progress with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. Journal of Clinical Oncology, 2020, 38, TPS459-TPS459.	0.8	0
107	P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases. Annals of Oncology, 2020, 31, S134-S135.	0.6	1
108	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. Blood, 2020, 136, 31-32.	0.6	0

#	Article	IF	Citations
109	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. Frontiers in Oncology, 2019, 9, 618.	1.3	9
110	EXCELLENT OUTCOMES USING RITUXIMAB, GEMCITABINE, CYCLOPHOSPHAMIDE, VINCRISTINE, PREDNISOLONE (R-GCVP) IN PATIENTS WITH DLBCL AND CARDIAC COMORBIDITIES. Hematological Oncology, 2019, 37, 425-426.	0.8	1
111	Efficacy of Vemurafenib in Patients With Nonâ€"Small-Cell Lung Cancer With BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2019, 3, 1-9.	1.5	31
112	ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clinical Colorectal Cancer, 2019, 18, 280-291.e5.	1.0	16
113	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. Cancer Cell, 2019, 36, 35-50.e9.	7.7	179
114	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncology, The, 2019, 20, 1109-1123.	5.1	193
115	The use of first, second and beyond line chemotherapy for metastatic pancreatic ductal adenocarcinoma at the Royal Marsden Hospital. Annals of Oncology, 2019, 30, iv108.	0.6	0
116	Identification of a nanostring signature that differentiates early pancreatic cancers according to stromal composition and predicts clinical outcome. Annals of Oncology, 2019, 30, iv110-iv111.	0.6	0
117	iSCORE: Immunotherapy sequencing in colon and rectal cancer. Annals of Oncology, 2019, 30, v248.	0.6	1
118	EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers. Annals of Oncology, 2019, 30, v251-v252.	0.6	3
119	Perioperative FLOT + anti-PD-L1 avelumab (FLOT-A) chemo-immunotherapy in resectable oesophagogastric adenocarcinoma (OGA): Safety and biomarker data from the ICONIC trial safety run-in. Annals of Oncology, 2019, 30, v254.	0.6	1
120	Outcomes of Patients with Early Onset Colorectal Cancer Treated in a UK Specialist Cancer Center. Cancers, 2019, 11, 1558.	1.7	25
121	Clonal diversity of MYC amplification evaluated by fluorescent inÂsitu hybridisation and digital droplet polymerase chain reaction in oesophagogastric cancer: Results from a prospective clinical trial screening programme. European Journal of Cancer, 2019, 122, 12-21.	1.3	2
122	Targeting EGFR pathway in metastatic colorectal cancer- tumour heterogeniety and convergent evolution. Critical Reviews in Oncology/Hematology, 2019, 143, 153-163.	2.0	49
123	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. European Journal of Cancer, 2019, 121, 40-47.	1.3	43
124	Comparison of Outcomes Between Patients with MYC Rearranged DLBCL and Double/Triple Hit High-Grade B-Cell Lymphoma: A Pan-London Retrospective Review. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S248.	0.2	0
125	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 420-435.	5.1	191
126	Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). Clinical Colorectal Cancer, 2019, 18, 183-191.e3.	1.0	16

#	Article	IF	Citations
127	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. Cancers, 2019, 11, 736.	1.7	15
128	Gastric Cancer â€“ From Aetiology to Management: Differences Between the East and the West. Clinical Oncology, 2019, 31, 570-577.	0.6	22
129	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Journal of the National Cancer Institute, 2019, 111, 782-794.	3.0	223
130	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
131	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. Clinical Cancer Research, 2019, 25, 3830-3838.	3.2	42
132	Do investigational MET inhibitors have potential for the treatment of gastric cancer?. Expert Opinion on Investigational Drugs, 2019, 28, 299-302.	1.9	2
133	Pseudoprogression on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. Current Problems in Cancer, 2019, 43, 487-494.	1.0	9
134	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
135	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage. Annals of Oncology, 2019, 30, vii5.	0.6	0
136	MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-NaÃ¯ve Non-Small Cell Lung Cancer (JVDF). Journal of Thoracic Oncology, 2019, 14, S307.	0.5	3
137	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. Cancer Treatment Reviews, 2019, 73, 31-40.	3.4	15
138	Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials. European Journal of Cancer, 2019, 107, 115-123.	1.3	33
139	A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. European Journal of Cancer, 2019, 108, 17-24.	1.3	32
140	Is front-line checkpoint blockade ATTRACTIVE in advanced gastric cancer?. Annals of Oncology, 2019, 30, 159-161.	0.6	6
141	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. Journal of Thoracic Oncology, 2019, 14, 237-244.	0.5	241
142	Ramucirumab and its use in the treatment of hepatocellular carcinoma. Future Oncology, 2019, 15, 979-988.	1.1	8
143	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	1.0	10
144	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) Â± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). Cancer Research, 2019, 79, 2673-2673.	0.4	17

#	Article	IF	Citations
145	Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC) Tj ETQq1 1 0.784314 rgBT /Over		
146	POLEM: Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancerâ€"A phase III randomized study.. Journal of Clinical Oncology, 2019, 37, TPS3615-TPS3615.	0.8	14
147	Comparative effectiveness of nivolumab (NIVO) relative to standard of care (SOC) for advanced/metastatic (adv/met) gastric or gastroesophageal junction cancer (GC/GEJC): A simulated treatment comparison (STC).. Journal of Clinical Oncology, 2019, 37, 128-128.	0.8	1
148	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	4
149	Real-world treatment patterns and clinical outcomes in patients receiving second-line (2L) treatment for advanced or metastatic gastric cancer (GC).. Journal of Clinical Oncology, 2019, 37, 102-102.	0.8	0
150	CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.. Journal of Clinical Oncology, 2019, 37, 535-535.	0.8	1
151	A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial. Blood, 2019, 134, 2879-2879.	0.6	0
152	Abstract 2673: Association of PD-L1 combined positive score and immune gene signatures with efficacy of nivolumab (NIVO) Â± ipilimumab (IPI) in patients with metastatic gastroesophageal cancer (mGEC). , 2019, , .		1
153	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	6.0	1,199
154	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncology, The, 2018, 19, e151-e160.	5.1	51
155	CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematology,the, 2018, 5, e190-e200.	2.2	50
156	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. Oncologist, 2018, 23, 822-839.	1.9	24
157	Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Review of Anticancer Therapy, 2018, 18, 327-338.	1.1	4
158	Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice. Annals of Oncology, 2018, 29, 230-236.	0.6	21
159	KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer. Scientific Reports, 2018, 8, 1445.	1.6	55
160	Chemotherapy for Advanced Pancreatic Cancer. , 2018, , 875-921.		0
161	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer, 2018, 17, e69-e76.	1.0	44
162	The costâ€effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. British Journal of Haematology, 2018, 180, 52-59.	1.2	8

#	Article	IF	Citations
163	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 814-824.	1.4	18
164	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, 2018, 67, 1780-1792.	6.1	19
165	Vemurafenib for BRAF V600â€"Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis. JAMA Oncology, 2018, 4, 384.	3.4	280
166	Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital. Leukemia and Lymphoma, 2018, 59, 1586-1595.	0.6	10
167	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59
168	PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENT. Value in Health, 2018, 21, S144.	0.1	0
169	BRAF Inhibition in BRAF^{V600}-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology, 2018, 36, 3477-3484.	0.8	247
170	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
171	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology, 2018, 36, 2836-2844.	0.8	459
172	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 280-291.	1.8	4
173	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric (OG) cancer: A pooled analysis of four randomised trials. Annals of Oncology, 2018, 29, viii721.	0.6	0
174	EGFR amplification (amp) and survival in the REAL-3 trial. Annals of Oncology, 2018, 29, viii217.	0.6	1
175	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF^{V600} Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO Precision Oncology, 2018, 2, 1-9.	1.5	20
176	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World Journal of Gastrointestinal Oncology, 2018, 10, 159-171.	0.8	10
177	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv238-iv255.	0.6	663
178	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). Heliyon, 2018, 4, e00804.	1.4	21
179	Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre. Anticancer Research, 2018, 38, 5943-5949.	0.5	2
180	Evolving Tissue and Circulating Biomarkers as Prognostic and Predictive Tools in Colorectal Cancer. Current Colorectal Cancer Reports, 2018, 14, 138-151.	1.0	0

#	Article	IF	Citations
181	Neoadjuvant rectal score: run with the hare and hunt with the hounds. Annals of Oncology, 2018, 29, 2261-2262.	0.6	9
182	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. Clinical Chemistry, 2018, 64, 1626-1635.	1.5	46
183	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. Cancer Discovery, 2018, 8, 1270-1285.	7.7	187
184	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33
185	Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clinical Colorectal Cancer, 2018, 17, 223-230.	1.0	27
186	Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patients. BMC Hematology, 2018, 18, 19.	2.6	6
187	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2018, 392, 123-133.	6.3	984
188	Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. British Journal of Cancer, 2018, 119, 19-26.	2.9	28
189	Session 3: Beyond <scp>TME</scp> and radiotherapy <scp>MRI</scp> evaluation of rectal cancer treatment response. Colorectal Disease, 2018, 20, 76-81.	0.7	5
190	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist, 2018, 23, 1407-e136.	1.9	127
191	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood, 2018, 132, 2892-2892.	0.6	4
192	Activity of ramucirumab (R) with pembrolizumab (P) by PD-L1 expression in advanced solid tumors: Phase 1a/b study in later lines of therapy.. Journal of Clinical Oncology, 2018, 36, 3059-3059.	0.8	3
193	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. Journal of Clinical Oncology, 2018, 36, e16207-e16207.	0.8	2
194	Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.. Journal of Clinical Oncology, 2018, 36, TPS4139-TPS4139.	0.8	4
195	Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naÃ¯ve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF).. Journal of Clinical Oncology, 2018, 36, 101-101.	0.8	21
196	Percutaneous radiofrequency versus microwave ablation for the treatment of colorectal liver metastases.. Journal of Clinical Oncology, 2018, 36, 401-401.	0.8	3
197	RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 5-5.	0.8	19
198	Survival of chemotherapy (chemo) refractory gastric or gastroesophageal junction cancer (GC/GEJC) patients from Flatiron Health (FH): Matched clinical characteristics to ATTRACTION-2 and CHECKMATE-032.. Journal of Clinical Oncology, 2018, 36, 51-51.	0.8	1

#	Article	IF	Citations
199	Molecular subtype assay to reveal anti-EGFR response sub-clones in colorectal cancer (CRC).. Journal of Clinical Oncology, 2018, 36, 658-658.	0.8	7
200	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, 90-90.	0.8	1
201	CheckMate 649: A randomized, multicenter, open-label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2018, 36, TPS192-TPS192.	0.8	20
202	CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS193-TPS193.	0.8	17
203	MORPHEUS: A phase Ib/II multi-trial platform evaluating the efficacy and safety of cancer immunotherapy (CIT)-based combinations in patients (pts) with gastric or pancreatic cancer.. Journal of Clinical Oncology, 2018, 36, TPS530-TPS530.	0.8	6
204	Genomic loss of heterozygosity and survival in the REAL3 trial. Oncotarget, 2018, 9, 36654-36665.	0.8	13
205	Complications and seeding risk after percutaneous liver biopsy in an oncological setting.. Journal of Clinical Oncology, 2018, 36, 246-246.	0.8	1
206	Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.. Journal of Clinical Oncology, 2018, 36, 4044-4044.	0.8	1
207	What is the outcome of receiving subsequent therapy among patients (pts) with advanced/metastatic (Adv/Met) gastric or gastroesophageal junction cancer (GC/GEJC)? Experience from electronic health records (EHR).. Journal of Clinical Oncology, 2018, 36, e16023-e16023.	0.8	0
208	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials.. Journal of Clinical Oncology, 2018, 36, e15127-e15127.	0.8	0
209	Abstract 4977: MIR1307 mediates pancreatic cancer resistance to FOLFIRINOX chemotherapy by affecting response to DNA damage. , 2018, , .		0
210	Abstract 4339: Molecular subtypes and novel genetic mechanisms of primary and acquired anti-EGFR resistance in colorectal cancer in the Prospect C biomarker trial. , 2018, , .		1
211	Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. Blood, 2018, 132, 4240-4240.	0.6	0
212	Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients. Oncologist, 2017, 22, 402-408.	1.9	31
213	Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. Canadian Journal of Cardiology, 2017, 33, 1336.e9-1336.e12.	0.8	3
214	Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy. Oncologist, 2017, 22, 728-736.	1.9	10
215	Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. European Journal of Cancer, 2017, 81, 17-25.	1.3	64
216	Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes. Clinical Cancer Research, 2017, 23, 6002-6011.	3.2	26

#	Article	IF	Citations
217	Emerging Novel Therapeutic Agents in the Treatment of Patients with Gastroesophageal and Gastric Adenocarcinoma. Hematology/Oncology Clinics of North America, 2017, 31, 529-544.	0.9	8
218	Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003â€"2013. Leukemia and Lymphoma, 2017, 58, 1805-1813.	0.6	13
219	Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Annals of Oncology, 2017, 28, 2932-2942.	0.6	93
220	Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?. Lancet, The, 2017, 390, 2418-2419.	6.3	24
221	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2017, 17, 951-964.	1.1	2
222	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. British Journal of Cancer, 2017, 117, 1478-1485.	2.9	118
223	Beyond genomics â€" Targeting the epigenome in diffuse large B-cell lymphoma. Cancer Treatment Reviews, 2017, 59, 132-137.	3.4	5
224	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncology, The, 2017, 18, 1159-1171.	5.1	293
225	Nivolumab monotherapy in patients with advanced gastric or gastroesophageal junction (GEJ) cancer and 2 or more prior treatment regimens: Sub-analysis of the CheckMate 032 study. Annals of Oncology, 2017, 28, iii139.	0.6	1
226	Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study. Annals of Oncology, 2017, 28, iii144-iii145.	0.6	1
227	BACCHUS: A randomised study of neoadjuvant chemotherapy alone in patients with high-risk locally advanced rectal cancer. Annals of Oncology, 2017, 28, iii126.	0.6	1
228	Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2017, 3, 235.	3.4	74
229	Attitudes of Patients With Gastrointestinal Cancers Toward Research Biopsies. Clinical Colorectal Cancer, 2017, 16, e181-e189.	1.0	6
230	Heterogeneity of MYC amplification in oesophagogastric (OG) carcinoma: Results from a prospective screening study. Annals of Oncology, 2017, 28, iii2-iii3.	0.6	0
231	Diagnostic accuracy and safety of coaxial core-needle biopsy (CNB) system in a predominanty gastrointestinal oncology patient population, treated at the Royal Marsden (RM) Hospital. Annals of Oncology, 2017, 28, iii6.	0.6	2
232	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. Journal of Gastric Cancer, 2017, 17, 132.	0.9	54
233	Associations of quality of life (QoL) with adverse events and tumor response in patients with advanced gastric cancer: Exploratory analyses from RAINBOW and REGARD. Annals of Oncology, 2017, 28, iii142-iii143.	0.6	1
234	Real world use of palliative systemic therapy (tx) in patients (pts) with metastatic early onset colorectal cancer (mEOCRC) within a UK specialist cancer centre. Annals of Oncology, 2017, 28, v202-v203.	0.6	0

#	Article	IF	Citations
235	Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 2017, 35, 2279-2287.	0.8	100
236	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. Journal of Clinical Oncology, 2017, 35, 2004-2004.	0.8	1
237	Nivolumab Â± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study.. Journal of Clinical Oncology, 2017, 35, 4014-4014.	0.8	53
238	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. Journal of Clinical Oncology, 2017, 35, 4046-4046.	0.8	14
239	Meaningful changes in quality of life (QoL) in patients with gastric cancer: Exploratory analyses from RAINBOW and REGARD.. Journal of Clinical Oncology, 2017, 35, 4047-4047.	0.8	1
240	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7537-7537.	0.8	2
241	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF^{V600} mutation.. Journal of Clinical Oncology, 2017, 35, 9074-9074.	0.8	10
242	CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS4131-TPS4131.	0.8	3
243	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS4132-TPS4132.	0.8	4
244	A prospective, randomized, double-blinded, placebo-controlled, phase III study to evaluate the efficacy and safety of apatinib plus best supportive care (BSC) compared to placebo plus BSC in patients with advanced or metastatic gastric cancer: The ANGEL study.. Journal of Clinical Oncology, 2017, 35, TPS4138-TPS4138.	0.8	1
245	Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).. Journal of Clinical Oncology, 2017, 35, TPS7579-TPS7579.	0.8	2
246	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. Journal of Clinical Oncology, 2017, 35, 102-102.	0.8	20
247	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials.. Journal of Clinical Oncology, 2017, 35, 3-3.	0.8	4
248	CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS212-TPS212.	0.8	16
249	Checkmate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (Nivo) plus ipilimumab (Ipi) versus oxaliplatin plus fluoropyrimidine in patients (Pts) with previously untreated advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) cancer.. Journal of Clinical Oncology, 2017, 35, TPS213-TPS213.	0.8	15
250	Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment. Oncotarget, 2017, 8, 64999-65008.	0.8	14
251	Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 333.	0.8	7
252	Chemotherapy for Advanced Pancreatic Cancer. , 2017, , 1-48.		0

#	Article	IF	Citations
253	iMYC: Proof-of-concept study of ibrutinib in c-MYC and HER2 amplified oesophagogastric carcinoma.. Journal of Clinical Oncology, 2017, 35, TPS221-TPS221.	0.8	1
254	Magnetic resonance Imaging (MRI), liquid biopsies, and patient derived organoids (PDOs) as biomarkers of response to regorafenib (REG) in treatment-refractory metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology, 2017, 35, 613-613.	0.8	7
255	Systemic chemotherapy (CT) as salvage treatment for locally advanced rectal cancer (LARC) patients (pts) who fail to respond to neoadjuvant chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2017, 35, 709-709.	0.8	49
256	KRAS mutations in circulating tumour DNA (ctDNA) in MRI-defined, high-risk, locally-advanced rectal cancer (LARC) patients (pts) from the EXPERT-C trial. Annals of Oncology, 2016, 27, vi173.	0.6	0
257	Association of disease measurability, quality of life (QoL) and tumor status in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) cancer. Annals of Oncology, 2016, 27, vi215.	0.6	0
258	Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. Translational Gastroenterology and Hepatology, 2016, 1, 46-46.	1.5	8
259	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget, 2016, 7, 12672-12681.	0.8	34
260	Platinum-fluoropyrimidine (PF) and paclitaxel (PTX)-based chemotherapy (CT) in advanced anal cancer (AC). Annals of Oncology, 2016, 27, vi166.	0.6	0
261	Investigating the feasibility of precision medicine in gastrointestinal cancers. Annals of Oncology, 2016, 27, vi216.	0.6	0
262	Chemotherapy for Advanced Pancreatic Cancer. , 2016, , 1-48.		0
263	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. Annals of Oncology, 2016, 27, 1557-1565.	0.6	64
264	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	7.7	222
265	Timing of Therapies in the Multidisciplinary Treatment of Locally Advanced Rectal Cancer: Available Evidence and Implications for Routine Practice. Seminars in Radiation Oncology, 2016, 26, 176-185.	1.0	6
266	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology, The, 2016, 17, 801-810.	5.1	719
267	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. Therapeutic Advances in Medical Oncology, 2016, 8, 104-112.	1.4	6
268	Colorectal cancer trial endpoints: time for dynamic thinking?. Lancet Oncology, The, 2016, 17, 1345-1347.	5.1	0
269	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. British Journal of Cancer, 2016, 115, 974-982.	2.9	53
270	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. Carcinogenesis, 2016, 37, 852-857.	1.3	15

#	Article	IF	Citations
271	Immunotherapy for oesophagogastric cancer. Expert Opinion on Biological Therapy, 2016, 16, 1197-1207.	1.4	10
272	Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade. Journal of Hepatology, 2016, 64, S693-S694.	1.8	1
273	Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging. Oncologist, 2016, 21, 1502-1508.	1.9	16
274	Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP). Annals of Oncology, 2016, 27, vi182.	0.6	4
275	Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) Â± panitumumab (P) in the REAL3 trial. Annals of Oncology, 2016, 27, vi220.	0.6	3
276	Novel STAT 3 inhibitors for treating gastric cancer. Expert Opinion on Investigational Drugs, 2016, 25, 1023-1031.	1.9	45
277	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology, The, 2016, 17, 883-895.	5.1	1,091
278	Patientsâ€™ willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials, 2016, 17, 17.	0.7	148
279	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer, 2016, 16, 112.	1.1	17
280	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. Clinical Colorectal Cancer, 2016, 15, e53-e59.	1.0	27
281	Management of resectable colorectal lung metastases. Clinical and Experimental Metastasis, 2016, 33, 285-296.	1.7	36
282	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. Drugs, 2016, 76, 13-26.	4.9	11
283	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. Expert Review of Hematology, 2016, 9, 123-135.	1.0	2
284	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001â€“2010. Gastric Cancer, 2016, 19, 1114-1124.	2.7	8
285	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. Blood, 2016, 128, 480-480.	0.6	5
286	Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies. Blood, 2016, 128, 624-624.	0.6	8
287	A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.. Journal of Clinical Oncology, 2016, 34, 3056-3056.	0.8	18
288	CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).. Journal of Clinical Oncology, 2016, 34, 4010-4010.	0.8	50

#	Article	IF	Citations
289	Phase II study of AZD4547 in FGFR amplified tumours: Gastroesophageal cancer (GC) cohort pharmacodynamic and biomarker results.. Journal of Clinical Oncology, 2016, 34, 154-154.	0.8	15
290	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. Journal of Clinical Oncology, 2016, 34, 6-6.	0.8	33
291	Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. Journal of Clinical Oncology, 2016, 34, 644-644.	0.8	1
292	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2016, 34, TPS178-TPS178.	0.8	2
293	PLATFORM: Planning treatment of oesophago-gastric (OG) cancerâ€"A randomised maintenance therapy trial.. Journal of Clinical Oncology, 2016, 34, TPS187-TPS187.	0.8	4
294	Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions. Current Drug Targets, 2016, 18, 56-71.	1.0	25
295	A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.. Journal of Clinical Oncology, 2016, 34, 580-580.	0.8	0
296	The EASI-SWITCH trial: Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis.. Journal of Clinical Oncology, 2016, 34, TPS10143-TPS10143.	0.8	0
297	Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases: Implications for targeted treatment.. Journal of Clinical Oncology, 2016, 34, e15027-e15027.	0.8	0
298	Abstract 69: Identification of new therapeutic targets and molecular predictors of response in oesophageal cancer. , 2016, , .		0
299	2188 Prognostic role of the LCS-6 KRAS variant in locally advanced rectal cancer: Results of the EXPERT-C trial. European Journal of Cancer, 2015, 51, S396.	1.3	0
300	P-309 PROSPECT-R: A PROSPECTive translational study investigating molecular predictors of resistance and response to Regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (CRC). Annals of Oncology, 2015, 26, iv91.	0.6	0
301	2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment. European Journal of Cancer, 2015, 51, S446.	1.3	1
302	2343 Quality of life (QoL) as a prognostic factor for survival in previously treated advanced gastric or gastroesophageal junction (GEJ) cancer: Analysis of pooled data from two phase 3 studies (REGARD) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.3	0
303	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. BMC Cancer, 2015, 15, 764.	1.1	32
304	The Role of Routine Clinical Pretreatment 18F-FDG PET/CT in Predicting Outcome of Colorectal Liver Metastasis. Clinical Nuclear Medicine, 2015, 40, e259-e264.	0.7	16
305	Pancreatic neuroendocrine tumors: a review. Future Oncology, 2015, 11, 853-864.	1.1	33
306	The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology. European Journal of Cancer, 2015, 51, 2732-2739.	1.3	5

#	Article	IF	Citations
307	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
308	The effect of a primary tumour resection on the progression of synchronous colorectal liver metastases: An exploratory study. European Journal of Surgical Oncology, 2015, 41, 484-492.	0.5	20
309	Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Annals of Oncology, 2015, 26, 702-708.	0.6	271
310	Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C Trial. International Journal of Radiation Oncology Biology Physics, 2015, 93, 303-312.	0.4	21
311	Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 859-870.	5.1	699
312	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of Oncology, 2015, 26, 1936-1941.	0.6	24
313	Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Annals of Oncology, 2015, 26, 804-811.	0.6	83
314	Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience. BMC Cancer, 2015, 15, 15.	1.1	35
315	PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews, 2015, 41, 893-903.	3.4	55
316	Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. Therapeutic Advances in Gastroenterology, 2015, 8, 373-383.	1.4	22
317	Does surgery have a role in managing incurable gastric cancer?. Nature Reviews Clinical Oncology, 2015, 12, 676-682.	12.5	96
318	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. New England Journal of Medicine, 2015, 373, 726-736.	13.9	1,483
319	Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (Râ€<scp>GEM</scp>â€P) is an effective regimen in relapsed diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2015, 94, 219-226.	1.1	11
320	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. Blood, 2015, 126, 4263-4263.	0.6	9
321	Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours.. Journal of Clinical Oncology, 2015, 33, 2508-2508.	0.8	32
322	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL).. Journal of Clinical Oncology, 2015, 33, 4029-4029.	0.8	3
323	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.. Journal of Clinical Oncology, 2015, 33, 4077-4077.	0.8	3
324	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).. Journal of Clinical Oncology, 2015, 33, TPS4131-TPS4131.	0.8	4

#	Article	IF	Citations
325	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated Î±-fetoprotein (AFP) from the randomized phase III REACH study.. Journal of Clinical Oncology, 2015, 33, 232-232.	0.8	14
326	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2015, 33, 581-581.	0.8	1
327	Toxicity and efficacy of salvage paclitaxel chemotherapy in Royal Marsden (RM) oesophagogastric adenocarcinoma (OGA) patients (pts).. Journal of Clinical Oncology, 2015, 33, 188-188.	0.8	0
328	A prospective patient (pt) survey on clinical trials.. Journal of Clinical Oncology, 2015, 33, 707-707.	0.8	0
329	Trends in resected oesophageal and gastric adenocarcinoma (OGA) outcomes: Royal Marsden (RM) experience 2001-2010.. Journal of Clinical Oncology, 2015, 33, 169-169.	0.8	1
330	Formulating a surveillance strategy following surgery for oesophagogastric cancer.. Journal of Clinical Oncology, 2015, 33, 153-153.	0.8	0
331	FOrMAT: Feasibility of a molecular characterization approach to treatment of patients (pts) with advanced gastrointestinal (GI) tumors.. Journal of Clinical Oncology, 2015, 33, TPS227-TPS227.	0.8	0
332	Prognostic factor analysis of overall survival (OS) in gastric cancer from two phase III studies of second-line ramucirumab (RAM) (REGARD and RAINBOW) using pooled individual patient (pt) data.. Journal of Clinical Oncology, 2015, 33, 4028-4028.	0.8	1
333	Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of REACH pts by Child-Pugh (CP) score.. Journal of Clinical Oncology, 2015, 33, 4108-4108.	0.8	0
334	Abstract 3589: Validation of the role of circulating tumor DNA (ctDNA) in tracking mechanisms of resistance to anti-EGFR monoclonal antibodies (AE-mABs): preliminary results of the PROSPECT-C prospective trial. , 2015, , .		0
335	Improved Survival in Peripheral T-Cell Lymphoma (PTCL) Following Complete Response to First-Line Chemotherapy: 10 Year Experience at the Royal Marsden and the Christie Hospitals 2002-2012. Blood, 2015, 126, 1499-1499.	0.6	0
336	Quality of Life and Bowel Function in Locally Advanced Rectal Cancer Patients Treated with an Intensified Neoadjuvant Regimen in the Expert-C Trial. Annals of Oncology, 2014, 25, iv199.	0.6	0
337	Factors Associated with Second Line Paclitaxel Efficacy in Non-Asian Patients (Pts) with Advanced Oesophagogastric (Og) Cancer. Annals of Oncology, 2014, 25, iv223.	0.6	0
338	Patients' (Pts) Perspectives of Clinical Trials at the Royal Marsden (Rm). Annals of Oncology, 2014, 25, iv485.	0.6	0
339	Designing Therapeutic Trial in Metastatic Gastric Cancer in 2014. Annals of Oncology, 2014, 25, v17.	0.6	0
340	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. Immunotherapy, 2014, 6, 1177-1186.	1.0	6
341	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. JAMA Surgery, 2014, 149, 18.	2.2	36
342	287 The discovery and optimization of small molecule antagonists of the WDR5â€"MLL interaction. European Journal of Cancer, 2014, 50, 95.	1.3	0

#	Article	IF	Citations
343	Investigational therapies targeting the ErbB family in oesophagogastric cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1349-1363.	1.9	3
344	FcÎ³RIIaandFcÎ³RIIIaPolymorphisms and Cetuximab Benefit in the Microscopic Disease. Clinical Cancer Research, 2014, 20, 4511-4519.	3.2	7
345	Optimal Management of Gastric Cancer. Annals of Surgery, 2014, 259, 102-108.	2.1	48
346	The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study. European Journal of Cancer, 2014, 50, 1422-1429.	1.3	28
347	GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Annals of Hematology, 2014, 93, 827-834.	0.8	8
348	What studies are appropriate and necessary for staging gastric adenocarcinoma? Results of an international RAND/UCLA expert panel. Gastric Cancer, 2014, 17, 377-382.	2.7	15
349	EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Annals of Oncology, 2014, 25, 858-863.	0.6	85
350	RAS mutations and cetuximab in locally advanced rectal cancer: Results of the EXPERT-C trial. European Journal of Cancer, 2014, 50, 1430-1436.	1.3	29
351	Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet, The, 2014, 383, 31-39.	6.3	1,833
352	FOLFIRINOX for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: The Royal Marsden Experience. Clinical Colorectal Cancer, 2014, 13, 232-238.	1.0	60
353	A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer. European Journal of Cancer, 2014, 50, 3136-3144.	1.3	17
354	Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. Clinical Cancer Research, 2014, 20, 5875-5881.	3.2	82
355	A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer, 2014, 14, 605.	1.1	32
356	Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, The, 2014, 15, e447-e460.	5.1	171
357	TP53 Mutational Status and Cetuximab Benefit in Rectal Cancer: 5-Year Results of the EXPERT-C Trial. Journal of the National Cancer Institute, 2014, 106, .	3.0	46
358	Extramural venous invasion is a potential imaging predictive biomarker of neoadjuvant treatment in rectal cancer. British Journal of Cancer, 2014, 110, 19-25.	2.9	130
359	Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology, The, 2014, 15, 78-86.	5.1	516
360	A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers. Clinical Colorectal Cancer, 2014, 13, 94-99.	1.0	28

#	Article	IF	Citations
361	Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer. Annals of the Royal College of Surgeons of England, 2014, 96, 543-546.	0.3	21
362	Is Stem Cell Transplantation for Transformed Follicular Lymphoma Required in the Rituximab Era?: The Royal Marsden Experience 2003-2013. Blood, 2014, 124, 1719-1719.	0.6	1
363	VE-BASKET, a first-in-kind, phase II, histology-independent â€œbasketâ€•study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. Journal of Clinical Oncology, 2014, 32, 2533-2533.	0.8	12
364	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. Journal of Clinical Oncology, 2014, 32, 3518-3518.	0.8	20
365	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2014, 32, 3575-3575.	0.8	7
366	Epidermal growth factor receptor copy number gain (EGFR CNG) and response to gefitinib in esophageal cancer (EC): Results of a biomarker analysis of a phase III trial of gefitinib versus placebo (TRANS-COG).. Journal of Clinical Oncology, 2014, 32, 4016-4016.	0.8	13
367	REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.. Journal of Clinical Oncology, 2014, 32, 4057-4057.	0.8	4
368	Quality of life (QoL) analysis from the randomized phase III REAL3 trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab (P) in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 4067-4067.	0.8	2
369	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2014, 32, TPS3114-TPS3114.	0.8	10
370	JAGUAR: A randomized phase II study of the AKT inhibitor ipatasertib (GDC-0068) versus placebo in combination with mFOLFOX6 chemotherapy in patients (pts) with locally advanced or metastatic HER2-negative gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS4147-TPS4147.	0.8	3
371	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. Journal of Clinical Oncology, 2014, 32, 489-489.	0.8	3
372	Colorectal cancer with liver metastases: Neoadjuvant chemotherapy, surgical resection first or palliation alone?. World Journal of Gastroenterology, 2014, 20, 12391.	1.4	48
373	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 447-447.	0.8	0
374	Prognostication in esophagogastric adenocarcinoma (OGA): Factors influencing overall survival (OS) in REAL3.. Journal of Clinical Oncology, 2014, 32, 91-91.	0.8	0
375	The impact of treatment intent on overall survival after radiofrequency ablation of colorectal cancer liver metastases: The Royal Marsden Hospital experience.. Journal of Clinical Oncology, 2014, 32, 622-622.	0.8	0
376	Fifteen-year experience of all patients (pts) with small bowel adenocarcinoma (SBA), treated in a specialized gastrointestinal (GI) oncology unit: Royal Marsden (RM) experience.. Journal of Clinical Oncology, 2014, 32, 316-316.	0.8	0
377	Exclusion of patients with prior cancers from clinical trials: Is this justified?. Journal of Clinical Oncology, 2014, 32, 6544-6544.	0.8	0
378	FCÎ³RIIa and FCÎ³RIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. Journal of Clinical Oncology, 2014, 32, 3573-3573.	0.8	0

#	Article	IF	Citations
379	LEGEND: A randomised phase II study comparing lenalidomide plus rituximab, gemcitabine, and methylprednisolone (R-GEM-L) to rituximab, gemcitabine, methylprednisolone, and cisplatin (R-GEM-P) in second-line treatment of diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2014, 32, TPS8618-TPS8618.	0.8	0
380	Bevacizumab and combination chemotherapy in rectal cancer until surgery (BACCHUS): A phase II, multicenter, open-label, randomized study of neoadjuvant chemotherapy alone without radiation in patients with MRI-defined high-risk cancer of the rectum not threatening the circumferential margin.. Journal of Clinical Oncology, 2014, 32, TPS3653-TPS3653.	0.8	0
381	Residual Disease on FDG-PET and Multiple Lines of Prior Therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem Cell Transplantation for Lymphoma. Blood, 2014, 124, 3971-3971.	0.6	0
382	Successful Long-Term Outcomes in Patients with Lymphoma Achieving Only Partial Response on [18f]FDG-PET Prior to Allogeneic Transplant. Blood, 2014, 124, 1249-1249.	0.6	0
383	The genomic landscape of oesophagogastric junctional adenocarcinoma. Journal of Pathology, 2013, 231, 301-310.	2.1	42
384	Defining Surgical Quality in Gastric Cancer: A RAND/UCLA Appropriateness Study. Journal of the American College of Surgeons, 2013, 217, 347-357e1.	0.2	42
385	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. European Journal of Cancer, 2013, 49, 2116-2125.	1.3	38
386	Neoadjuvant therapy before surgical treatment. European Journal of Cancer, Supplement, 2013, 11, 45-59.	2.2	7
387	Aflibercept + FOLFIRI (AF) Versus. Placebo + FOLFIRI (PF) in Metastatic Colorectal Cancer (mCRC): Mean Overall Survival (OS) in a â€œBetter Respondersâ€•Patient Population of the Velour Trial. Value in Health, 2013, 16, A397-A398.	0.1	0
388	Perioperative Chemotherapy With or Without Bevacizumab in Patients With Metastatic Colorectal Cancer Undergoing Liver Resection. Clinical Colorectal Cancer, 2013, 12, 15-22.	1.0	22
389	A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO). European Journal of Cancer, 2013, 49, 3507-3516.	1.3	21
390	What provider volumes and characteristics are appropriate for gastric cancer resection? Results ofÂanÂinternational RAND/UCLA expertÂpanel. Surgery, 2013, 154, 1100-1109.	1.0	14
391	MRI Predictive Factors for Tumor Response in Rectal Cancer Following Neoadjuvant Chemoradiation Therapy - Implications for Induction Chemotherapy?. International Journal of Radiation Oncology Biology Physics, 2013, 87, 505-511.	0.4	63
392	Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2013, 14, 481-489.	5.1	631
393	Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncology, The, 2013, 14, 749-759.	5.1	333
394	A RAND/UCLA Appropriateness Study of the Management of Familial Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 533-541.	0.7	12
395	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Investigational New Drugs, 2013, 31, 1228-1235.	1.2	7
396	Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial. Investigational New Drugs, 2013, 31, 1339-1344.	1.2	8

#	Article	IF	Citations
397	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. Annals of Oncology, 2013, 24, 3123-3128.	0.6	32
398	The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis. British Journal of Radiology, 2013, 86, 20130281.	1.0	32
399	Gemcitabine Plus Capecitabine in Unselected Patients With Advanced Pancreatic Cancer. Pancreas, 2013, 42, 511-515.	0.5	9
400	Selecting Patients With Locally Advanced Rectal Cancer for Neoadjuvant Treatment Strategies. Oncologist, 2013, 18, 833-842.	1.9	12
401	Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. European Journal of Cancer Care, 2013, 22, 714-725.	0.7	38
402	ANTI-CD30 Antibody Drug Conjugate Therapy in Hodgkin Lymphoma and CD30+ Lymphoma. Annals of Oncology, 2013, 24, ix18.	0.6	0
403	Rare case of cerebral MALToma presenting with stroke-like symptoms and seizures. BMJ Case Reports, 2013, 2013, bcr2012008494-bcr2012008494.	0.2	5
404	HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2013, 31, e14616-e14616.	0.8	1
405	HER-2 in high risk rectal cancer patients treated inÂEXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2013, 31, 420-420.	0.8	2
406	COUGAR-02: A randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, LBA4-LBA4.	0.8	14
407	REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and/or fluoropyrimidine-containing combination therapy.. Journal of Clinical Oncology, 2013, 31, LBA5-LBA5.	0.8	16
408	Association of high-throughput RNAi and drug screening with candidate novel therapeutic targets in esophageal carcinoma.. Journal of Clinical Oncology, 2013, 31, 31-31.	0.8	0
409	Reporting of subgroup analyses (SGA) in phase III randomized trials in gastrointestinal (GI) cancer.. Journal of Clinical Oncology, 2013, 31, 78-78.	0.8	0
410	Abstract LB-67: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p. , 2013, , .		1
411	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology, 2012, 23, 119-127.	0.6	23
412	A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Annals of Oncology, 2012, 23, 942-947.	0.6	12
413	Primary Follicular Lymphoma of the GI Tract: An Increasingly Recognized Entity. Journal of Clinical Oncology, 2012, 30, e370-e372.	0.8	5
414	Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. British Journal of Cancer, 2012, 106, 1718-1721.	2.9	30

#	Article	IF	Citations
415	Preoperative and Postoperative Chemotherapy for Gastric Cancer. Surgical Oncology Clinics of North America, 2012, 21, 99-112.	0.6	20
416	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer, 2012, 12, 326.	1.1	26
417	Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C). Journal of Clinical Oncology, 2012, 30, 1620-1627.	0.8	357
418	A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. Journal of Clinical Oncology, 2012, 30, LBA4000-LBA4000.	0.8	1
419	A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).. Journal of Clinical Oncology, 2012, 30, LBA4000-LBA4000.	0.8	34
420	Impact of mismatch repair (MMR) testing on colorectal cancer (CRC) oncology clinical practice.. Journal of Clinical Oncology, 2012, 30, 603-603.	0.8	1
421	A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR).. Journal of Clinical Oncology, 2012, 30, TPS4146-TPS4146.	0.8	3
422	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. Journal of Clinical Oncology, 2012, 30, e14088-e14088.	0.8	0
423	6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer â€“ Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification. European Journal of Cancer, 2011, 47, S420-S421.	1.3	2
424	Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology, 2011, 8, 492-503.	12.5	132
425	Nonsurgical Management of Esophageal Adenocarcinoma. Clinical Colorectal Cancer, 2011, 10, 165-170.	1.0	1
426	Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. European Journal of Cancer, 2011, 47, 1146-1151.	1.3	29
427	Timing of Surgery Following Preoperative Therapy in Rectal Cancer: The Need for a Prospective Randomized Trial?. Diseases of the Colon and Rectum, 2011, 54, 1251-1259.	0.7	58
428	Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. British Journal of Cancer, 2011, 104, 43-50.	2.9	12
429	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology, 2011, 21, 196-202.	1.0	8
430	Patupilone in cancer treatment. Expert Opinion on Investigational Drugs, 2011, 20, 107-117.	1.9	28
431	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Annals of Oncology, 2011, 22, 2042-2048.	0.6	197
432	EXPERT-C: A randomized, phase II European multicenter trial of neoadjuvant capecitabine plus oxaliplatin chemotherapy (CAPOX) and chemoradiation (CRT) with or without cetuximab followed by total mesorectal excision (TME) in patients with MRI-defined, high-risk rectal cancer.. Journal of Clinical Oncology, 2011, 29, 3513-3513.	0.8	8

#	Article	IF	Citations
433	Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).. Journal of Clinical Oncology, 2011, 29, 3523-3523.	0.8	21
434	REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancerâ€"Response rate (RR), toxicity, and molecular analysis from phase II.. Journal of Clinical Oncology, 2011, 29, 4131-4131.	0.8	7
435	Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom.. Journal of Clinical Oncology, 2011, 29, 489-489.	0.8	17
436	Prospective study of genetic mutations in matched tumor and plasma specimens in colorectal cancer patients.. Journal of Clinical Oncology, 2011, 29, 356-356.	0.8	0
437	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. British Journal of Cancer, 2010, 102, 255-261.	2.9	9
438	The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Annals of Oncology, 2010, 21, 1013-1019.	0.6	46
439	Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial. Journal of Clinical Oncology, 2010, 28, 3945-3950.	0.8	118
440	Trastuzumab for gastric cancer treatment. Lancet, The, 2010, 376, 1736.	6.3	6
441	Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncology, The, 2010, 11, 241-248.	5.1	305
442	Chemotherapy for Advanced Pancreatic Cancer. , 2010, , 913-949.		1
443	A multicenter phase II clinical study evaluating the deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2010, 28, TPS191-TPS191.	0.8	3
444	A multicenter randomized phase II study of UFT/leucovorin and radiotherapy (RT) with or without cetuximab following induction gemcitabine plus capecitabine (GEM-CAP) in locally advanced pancreatic cancer (LAPC).. Journal of Clinical Oncology, 2010, 28, TPS221-TPS221.	0.8	0
445	Assessment of combination treatment with gemcitabine, cisplatin, and methylprednisolone (Gem-P) in the management of non-Hodgkin T-cell lymphoma.. Journal of Clinical Oncology, 2010, 28, 8052-8052.	0.8	0
446	RCHOPB: Feasibility study of RCHOP plus bevacizumab (B) in patients (pts) with diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2010, 28, TPS304-TPS304.	0.8	0
447	MESH: Phase II trial of methotrexate as a synthetic lethal therapy for metastatic MSH2-deficient colorectal and other tumors.. Journal of Clinical Oncology, 2010, 28, TPS338-TPS338.	0.8	0
448	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	0.8	708
449	The impact of primary tumour origins in patients with advanced oesophageal, oesophagoâ€"gastric junction and gastric adenocarcinomaâ€"individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology, 2009, 20, 885-891.	0.6	50
450	Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5499-5505.	0.8	23

#	Article	IF	Citations
451	Validation of the Royal Marsden Hospital Prognostic Index in Advanced Esophagogastric Cancer Using Individual Patient Data From the REAL 2 Study. Journal of Clinical Oncology, 2009, 27, e3-e4.	0.8	46
452	Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer, 2009, 100, 1704-1719.	2.9	89
453	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. British Journal of Cancer, 2009, 100, 1725-1730.	2.9	20
454	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 2009, 101, 1033-1038.	2.9	154
455	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
456	Bevacizumab-associated gastrointestinal perforation. Lancet Oncology, The, 2009, 10, 534-536.	5.1	10
457	6076 BOXER: A multicentre phase II trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with liver-only metastases from colorectal cancer unsuitable for upfront resection. European Journal of Cancer, Supplement, 2009, 7, 344-345.	2.2	14
458	Longitudinal Assessment of Quality of Life in Rectal Cancer Patients With or Without Stomas Following Primary Resection. Diseases of the Colon and Rectum, 2009, 52, 669-677.	0.7	54
459	Insulin-Like Growth Factor 1 Receptor Targeted Therapeutics: Novel Compounds and Novel Treatment Strategies for Cancer Medicine. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 54-72.	0.8	125
460	Evaluating Mesorectal Lymph Nodes in Rectal Cancer Before and After Neoadjuvant Chemoradiation Using Thin-Section T2-Weighted Magnetic Resonance Imaging. International Journal of Radiation Oncology Biology Physics, 2008, 71, 456-461.	0.4	126
461	Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. European Radiology, 2008, 18, 903-910.	2.3	145
462	Capecitabine in gastric cancer. Drugs of Today, 2008, 44, 629.	0.7	7
463	Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology, 2007, 12, 149-153.	0.7	13
464	Capecitabine in advanced gastric cancer. Expert Opinion on Pharmacotherapy, 2007, 8, 2851-2861.	0.9	4
465	Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase Iâ€"II study. Annals of Oncology, 2007, 18, 730-737.	0.6	31
466	Mucosa associated lymphoid tissue lymphoma of the lung: The Royal Marsden Hospital experience. Leukemia and Lymphoma, 2007, 48, 547-550.	0.6	17
467	Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica, 2007, 92, 271-272.	1.7	90
468	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imagingâ€"Defined Poor-Risk Rectal Cancer. Journal of Clinical Oncology, 2006, 24, 668-674.	0.8	432

#	Article	IF	Citations
469	Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. British Journal of Cancer, 2006, 94, 1107-1115.	2.9	71
470	Folate Metabolism Polymorphisms Influence Risk of Colorectal Adenoma Recurrence. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1607-1613.	1.1	36
471	Adjuvant therapy in colon cancerâ€"what, when and how?. Annals of Oncology, 2006, 17, 1347-1359.	0.6	142
472	Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. British Journal of Cancer, 2005, 92, 1352-1357.	2.9	56
473	A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Annals of Oncology, 2005, 16, 549-557.	0.6	168
474	Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer. European Journal of Cancer, 2005, 41, 1551-1559.	1.3	20
475	A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitorâ€"Resistant Advanced Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 3023-3031.	0.8	42
476	Multivariate Prognostic Factor Analysis in Locally Advanced and Metastatic Esophago-Gastric Cancerâ€"Pooled Analysis From Three Multicenter, Randomized, Controlled Trials Using Individual Patient Data. Journal of Clinical Oncology, 2004, 22, 2395-2403.	0.8	455
477	The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 1420-1429.	0.8	153
478	Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. British Journal of Cancer, 2004, 91, 1453-1458.	2.9	67
479	Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. New England Journal of Medicine, 2004, 351, 337-345.	13.9	4,721
480	The vital role of education and information in patients receiving capecitabine (XelodaÂ®). European Journal of Oncology Nursing, 2004, 8, S41-S53.	0.9	38
481	Matrix metalloproteinase inhibitorsâ€"an emphasis on gastrointestinal malignancies. Critical Reviews in Oncology/Hematology, 2003, 45, 151-176.	2.0	23
482	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 120, 970-977.	1.2	56
483	Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil. British Journal of Cancer, 2003, 88, 1510-1515.	2.9	16
484	Overview of Preoperative and Postoperative Therapy for Colorectal Cancer: The European and United States Perspectives. Clinical Colorectal Cancer, 2003, 3, 19-33.	1.0	32
485	Impact of 5-Fluorouracil Rechallenge on Subsequent Response and Survival in Advanced Colorectal Cancer: Pooled Analysis from Three Consecutive Randomized Controlled Trials. Clinical Colorectal Cancer, 2003, 3, 102-107.	1.0	9
486	Oxaliplatin for Colorectal Cancer in the United States: Better Late Than Never. Journal of Clinical Oncology, 2003, 21, 2049-2051.	0.8	14

#	Article	IF	Citations
487	Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. British Journal of Cancer, 2003, 88, 1017-1024.	2.9	78
488	Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?. British Journal of Cancer, 2003, 89, 36-42.	2.9	68
489	Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. British Journal of Cancer, 2003, 88, 1859-1865.	2.9	78
490	Cyclooxygenase Inhibition in Cancer â€" A Blind Alley or a New Therapeutic Reality?. New England Journal of Medicine, 2002, 346, 1085-1087.	13.9	28
491	Chemotherapy in colorectal cancer: new options and new challenges. British Medical Bulletin, 2002, 64, 159-180.	2.7	34
492	Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer. Journal of Clinical Oncology, 2002, 20, 3130-3136.	0.8	132
493	Gemcitabine and Its Combinations in the Treatment of Malignant Lymphoma. Clinical Lymphoma and Myeloma, 2002, 3, 97-104.	2.1	18
494	Adjuvant therapy in colon cancer: current status and future directions. Cancer Treatment Reviews, 2002, 28, 223-236.	3.4	48
495	An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. British Journal of Haematology, 2001, 115, 786-792.	1.2	58
496	Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. British Journal of Cancer, 2001, 85, 1258-1264.	2.9	25
497	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. F1000Research, 0, 10, 1137.	0.8	0
498	Relationship Between Baseline Rectal Tumor Length and Magnetic Resonance Tumor Regression Grade Response to Chemoradiotherapy: A Subanalysis of the TRIGGER Feasibility Study. Annals of Surgical Oncology, 0, , .	0.7	1